Browse TAF1

Summary
SymbolTAF1
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa
Aliases TAFII250; DYT3/TAF1; BA2R; CCG1; CCGS; DYT3; TATA box binding protein (TBP)-associated factor, RNA polymeras ......
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00439 Bromodomain
PF12157 Protein of unknown function (DUF3591)
PF09247 TATA box-binding protein binding
Function

Largest component and core scaffold of the TFIID basal transcription factor complex (PubMed:25412659, PubMed:27007846). Contains novel N- and C-terminal Ser/Thr kinase domains which can autophosphorylate or transphosphorylate other transcription factors. Phosphorylates TP53 on 'Thr-55' which leads to MDM2-mediated degradation of TP53. Phosphorylates GTF2A1 and GTF2F1 on Ser residues. Possesses DNA-binding activity (PubMed:25412659). Essential for progression of the G1 phase of the cell cycle (PubMed:11278496, PubMed:15053879, PubMed:2038334, PubMed:8450888, PubMed:8625415, PubMed:9660973, PubMed:9858607). Exhibits histone acetyltransferase activity towards histones H3 and H4 (PubMed:15870300).

> Gene Ontology
 
Biological Process GO:0006352 DNA-templated transcription, initiation
GO:0006354 DNA-templated transcription, elongation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010498 proteasomal protein catabolic process
GO:0016570 histone modification
GO:0016573 histone acetylation
GO:0018105 peptidyl-serine phosphorylation
GO:0018107 peptidyl-threonine phosphorylation
GO:0018205 peptidyl-lysine modification
GO:0018209 peptidyl-serine modification
GO:0018210 peptidyl-threonine modification
GO:0018393 internal peptidyl-lysine acetylation
GO:0018394 peptidyl-lysine acetylation
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031334 positive regulation of protein complex assembly
GO:0032434 regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0042176 regulation of protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043254 regulation of protein complex assembly
GO:0043543 protein acylation
GO:0044089 positive regulation of cellular component biogenesis
GO:0045732 positive regulation of protein catabolic process
GO:0045862 positive regulation of proteolysis
GO:0046777 protein autophosphorylation
GO:0051123 RNA polymerase II transcriptional preinitiation complex assembly
GO:0060260 regulation of transcription initiation from RNA polymerase II promoter
GO:0060261 positive regulation of transcription initiation from RNA polymerase II promoter
GO:0061136 regulation of proteasomal protein catabolic process
GO:0065004 protein-DNA complex assembly
GO:0070897 DNA-templated transcriptional preinitiation complex assembly
GO:0071824 protein-DNA complex subunit organization
GO:0072331 signal transduction by p53 class mediator
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1901800 positive regulation of proteasomal protein catabolic process
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903052 positive regulation of proteolysis involved in cellular protein catabolic process
GO:1903362 regulation of cellular protein catabolic process
GO:1903364 positive regulation of cellular protein catabolic process
GO:2000142 regulation of DNA-templated transcription, initiation
GO:2000144 positive regulation of DNA-templated transcription, initiation
Molecular Function GO:0000983 transcription factor activity, RNA polymerase II core promoter sequence-specific
GO:0001075 transcription factor activity, RNA polymerase II core promoter sequence-specific binding involved in preinitiation complex assembly
GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding
GO:0001083 transcription factor activity, RNA polymerase II basal transcription factor binding
GO:0001129 RNA polymerase II transcription factor activity, TBP-class protein binding, involved in preinitiation complex assembly
GO:0001132 RNA polymerase II transcription factor activity, TBP-class protein binding
GO:0002039 p53 binding
GO:0003713 transcription coactivator activity
GO:0004402 histone acetyltransferase activity
GO:0004674 protein serine/threonine kinase activity
GO:0008080 N-acetyltransferase activity
GO:0008134 transcription factor binding
GO:0016407 acetyltransferase activity
GO:0016410 N-acyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
GO:0017025 TBP-class protein binding
GO:0034212 peptide N-acetyltransferase activity
GO:0042393 histone binding
GO:0061733 peptide-lysine-N-acetyltransferase activity
GO:0070577 lysine-acetylated histone binding
Cellular Component GO:0000428 DNA-directed RNA polymerase complex
GO:0005667 transcription factor complex
GO:0005669 transcription factor TFIID complex
GO:0016591 DNA-directed RNA polymerase II, holoenzyme
GO:0030880 RNA polymerase complex
GO:0034708 methyltransferase complex
GO:0035097 histone methyltransferase complex
GO:0044665 MLL1/2 complex
GO:0044798 nuclear transcription factor complex
GO:0055029 nuclear DNA-directed RNA polymerase complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0071339 MLL1 complex
GO:0090575 RNA polymerase II transcription factor complex
> KEGG and Reactome Pathway
 
KEGG hsa03022 Basal transcription factors
Reactome R-HSA-1643685: Disease
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167161: HIV Transcription Initiation
R-HSA-5663205: Infectious disease
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-167162: RNA Polymerase II HIV Promoter Escape
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73776: RNA Polymerase II Promoter Escape
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75953: RNA Polymerase II Transcription Initiation
R-HSA-76042: RNA Polymerase II Transcription Initiation And Promoter Clearance
R-HSA-73779: RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-167172: Transcription of the HIV genome
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolTAF1
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa
Aliases TAFII250; DYT3/TAF1; BA2R; CCG1; CCGS; DYT3; TATA box binding protein (TBP)-associated factor, RNA polymeras ......
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TAF1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTAF1
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa
Aliases TAFII250; DYT3/TAF1; BA2R; CCG1; CCGS; DYT3; TATA box binding protein (TBP)-associated factor, RNA polymeras ......
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TAF1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.53 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTAF1
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa
Aliases TAFII250; DYT3/TAF1; BA2R; CCG1; CCGS; DYT3; TATA box binding protein (TBP)-associated factor, RNA polymeras ......
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TAF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0110.961
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1540.9
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1320.887
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0340.915
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1490.958
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2650.941
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2980.401
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3130.849
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3160.86
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5570.649
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3270.434
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0390.366
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TAF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.18.22.90.699
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.110.20.91
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.118.8-7.71
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTAF1
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa
Aliases TAFII250; DYT3/TAF1; BA2R; CCG1; CCGS; DYT3; TATA box binding protein (TBP)-associated factor, RNA polymeras ......
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TAF1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTAF1
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa
Aliases TAFII250; DYT3/TAF1; BA2R; CCG1; CCGS; DYT3; TATA box binding protein (TBP)-associated factor, RNA polymeras ......
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TAF1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TAF1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTAF1
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa
Aliases TAFII250; DYT3/TAF1; BA2R; CCG1; CCGS; DYT3; TATA box binding protein (TBP)-associated factor, RNA polymeras ......
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TAF1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTAF1
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa
Aliases TAFII250; DYT3/TAF1; BA2R; CCG1; CCGS; DYT3; TATA box binding protein (TBP)-associated factor, RNA polymeras ......
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TAF1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTAF1
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa
Aliases TAFII250; DYT3/TAF1; BA2R; CCG1; CCGS; DYT3; TATA box binding protein (TBP)-associated factor, RNA polymeras ......
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TAF1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTAF1
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa
Aliases TAFII250; DYT3/TAF1; BA2R; CCG1; CCGS; DYT3; TATA box binding protein (TBP)-associated factor, RNA polymeras ......
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TAF1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.